<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Walter</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kitakaze, Masafumi</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Carperitide and Nicorandil on Injury and Function in Patients with Acute MI: Results of the J-WIND Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-20</style></pages><abstract><style  face="normal" font="default" size="100%">The results of the Japanese Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by Atrial Natriuretic Peptide (ANP) or Nicorandil [J-WIND] trials conducted in Japan from 2001–2006. Carperitide, human recombinant ANP, is approved for the treatment of acute heart failure in Japan. Nicorandil, a nicotinamide nitrate that activates potassium channels in the heart, is used to treat chronic angina. These randomized, double-blind studies evaluated intervention with either carperitide or nicorandil on infarct size, left ventricular function, and associated outcomes.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>